Clinical trials: Symptoms, Behavioral
Major Depressive Disorder (MDD)
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif XCS System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE-M (NCT07684794)
- Testing
- Motif XCS System
- Volunteers
- 10 people
- Sponsor
- Motif Neurotech, Inc.
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 49 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression
Pediatric Bipolar Depression
The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with…
- Trial name
- NCT00811473
- Testing
- Quetiapine XR
- Where
- 48 sites in United States, Colombia and 5 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Pain, Cancer Pain
Assessment of Updated Educational Materials for Instanyl®
The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use.
- Trial name
- NCT04938440
- Where
- United States
- Volunteers
- 536 people
- Sponsor
- Takeda
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00384033
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Duloxetine 60 mg/day
- Where
- 22 sites in United States
- Volunteers
- 638 people
- Sponsor
- Pfizer
Opioid-use Disorder, Depression, Anxiety
Transcranial Photobiomodulation for the Treatment of Opioid Cravings
The investigators wish to test the hypothesis that transcranial photobiomodulation (tPBM) (i.e., 4-minutes of 810nm near-infrared light at 250 mW/cm2 by LED to the forehead at F3 or F4 versus an indistinguishable placebo…
- Conditions
- Opioid-use Disorder, Depression, Anxiety, Craving
- Trial name
- NCT04417738
- Testing
- unilateral transcranial photobiomodulation, near infrared mode
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MindLight, LLC
Tinnitus
Mahana Tinnitus Pilot
The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ Tinnitus together with care as usual in approximately 250 adults with symptoms of tinnitus.
- Trial name
- NCT05696158
- Testing
- MHNA-003
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Mahana Therapeutics
Agitation in Dementia, Including Alzheimer's Disease
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including…
- Trial name
- NCT02817906
- Testing
- ITI-007
- Where
- 26 sites in United States
- Volunteers
- 177 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Stress
Evaluate the Effects of a Theanine Formulation on Stress, Burnout, Mood, and Sleep in Individuals Who Report Occasional Moderate or High Levels of Stress
The purpose of this study is to assess the effectiveness and safety of the theanine formulation on stress, burnout, mood, and sleep in male and female subjects who are generally healthy
- Trial name
- NCT05450952
- Testing
- Theanine Formulation
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Mental Fatigue
Brain Oxygenation Marker for Cognitive Function in Healthy Adults
This study aims to identify a cortical oxygenation marker for cognitive function using functional Near Infrared Spectroscopy in healthy adults.
- Trial name
- NCT05559034
- Testing
- Cognitive intervention
- Where
- Switzerland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Hyperphagia in Prader-Willi Syndrome
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intranasal FE 992097 in children and adults with Prader-Willi Syndrome.
- Trial name
- NCT01968187
- Testing
- FE 992097
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Ferring Pharmaceuticals
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT02196506
- Testing
- Brexpiprazole +ADT
- Where
- 47 sites in United States, Germany and 3 more
- Volunteers
- 837 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Brain Fog, Cognitive Health
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health.
- Trial name
- NBF-MG01 (NCT06695910)
- Testing
- Monoglyceride Eicosapentaenoic acid (omega-3), Sunflower Oil
- Where
- 2 sites in Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Samuel Fortin
Stress, Emotional Wellbeing
Prospective Real World Study on Therapy Prediction Algorithm Training
This study examines the impact of using an algorithm to select therapy content for patients engaged with the mobile mental health platform AmDTx (Mobio Interactive).
- Trial name
- NCT06265909
- Testing
- AmDTx
- Where
- Singapore
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Mobio Interactive PTE LTD
Stress Disorders, Post-Traumatic, Anxiety Disorders
Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics
This is an observational study to assess the change in several psychological screening tools before and after a series of six ketamine infusions in paramedics who suffer from post traumatic stress disorder as a result of working…
- Trial name
- NCT03947099
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Klarisana Physician Services PLLC
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Traumatic Brain Injury, Intracranial Hemorrhages
Usability Study of CEREBO® - A Novel Non-invasive Intracranial Bleed Detector
Traumatic Brain Injury (TBI) is the leading cause of death and disability across the globe. Time from injury to treatment is the most critical factor that determines the patient's recovery.
- Trial name
- NCT05340114
- Testing
- CEREBO®
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bioscan Research Pvt. Ltd.
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.